[{"address1": "369 South San Antonio Road", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 47, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 705653, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 35, "title": "CFO & Secretary", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 624125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Berman", "age": 44, "title": "Vice President of Finance & Accounting", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 49, "title": "General Counsel & Chief Administrative Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 49, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fadi  Abdel M.D.", "age": 45, "title": "Senior Vice President of Innovation", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.41, "open": 4.32, "dayLow": 4.1, "dayHigh": 4.455, "regularMarketPreviousClose": 4.41, "regularMarketOpen": 4.32, "regularMarketDayLow": 4.1, "regularMarketDayHigh": 4.455, "forwardPE": -1.5156795, "volume": 283044, "regularMarketVolume": 283044, "averageVolume": 736868, "averageVolume10days": 239320, "averageDailyVolume10Day": 239320, "bid": 4.1, "ask": 4.38, "bidSize": 800, "askSize": 800, "marketCap": 117320368, "fiftyTwoWeekLow": 3.56, "fiftyTwoWeekHigh": 24.0, "fiftyDayAverage": 4.1632, "twoHundredDayAverage": 10.3962, "currency": "USD", "enterpriseValue": -49618200, "floatShares": 19396734, "sharesOutstanding": 26970200, "sharesShort": 4071061, "sharesShortPriorMonth": 4661129, "sharesShortPreviousMonthDate": 1731628800, "dateShortInterest": 1734048000, "sharesPercentSharesOut": 0.1509, "heldPercentInsiders": 0.07509, "heldPercentInstitutions": 0.91299003, "shortRatio": 11.58, "shortPercentOfFloat": 0.1916, "impliedSharesOutstanding": 26970200, "bookValue": 6.12, "priceToBook": 0.7107843, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -57447000, "trailingEps": -2.38, "forwardEps": -2.87, "enterpriseToEbitda": 0.788, "52WeekChange": -0.78985506, "SandP52WeekChange": 0.22263205, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ANRO", "underlyingSymbol": "ANRO", "shortName": "Alto Neuroscience, Inc.", "firstTradeDateEpochUtc": 1706884200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "de8f86a8-e9a0-3331-96ee-f60530d2d3c7", "messageBoardId": "finmb_1675972978", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.35, "targetHighPrice": 18.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.72333, "targetMedianPrice": 13.5, "recommendationMean": 1.28571, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 181700992, "totalCashPerShare": 6.738, "ebitda": -62934000, "totalDebt": 14772000, "quickRatio": 12.965, "currentRatio": 13.095, "debtToEquity": 8.95, "returnOnAssets": -0.32356, "returnOnEquity": -0.56723, "freeCashflow": -35431000, "operatingCashflow": -45927000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]